Silencing of miR-34a Attenuates Cardiac Dysfunction in a Setting of Moderate, but Not Severe, Hypertrophic Cardiomyopathy
Figure 4
Cardiac stress gene expression and fibrosis in moderate and severe models of pressure overload.
(A) Northern blots and quantification of Anp, Bnp, and Serca2a relative to Gapdh, in hearts of control (con), TAC moderate (mod), TAC severe (sev) mice dosed with either LNA-control (c) or LNA-antimiR-34a (a). For Northern blot of Anp, a light exposure (light exp) and dark exposure (dark exp) has been included. N = 3–5 per group. ***P<0.001 vs. control, **P<0.01 vs. control, *P<0.05 vs. control, §P<0.05, †P<0.05, 1 way ANOVA followed by Fisher’s Post Hoc Test (comparing all five groups). When performing 1 way ANOVA followed by Fisher’s Post Hoc Test on control and TAC severe groups only (comparing three groups), N = 3 per group, or control and TAC moderate groups only (comparing three groups), N = 3–5 per group, ∧P<0.05 vs. control. (B) qPCR of β-MHC relative to Hprt1 in control, TAC moderate and TAC severe mice dosed with LNA-control or LNA-antimiR-34a. N = 3–5 per group. *P<0.05 vs. control, §P<0.05, ‡P<0.05 vs. control, 1 way ANOVA followed by Fisher’s Post Hoc Test (comparing all 5 groups). (C) LV cross-sections stained with Masson’s trichrome and quantification of LV fibrosis in control, TAC moderate and TAC severe mice dosed with LNA-control or LNA-antimiR-34a. Scale = 200 µM. N = 4–5 per group. ***P<0.001 vs. control, §P<0.05 vs. TAC-moderate of the same treatment group, 1 way ANOVA followed by Fisher’s Post Hoc Test (comparing all five groups). When comparing control and TAC moderate groups only (comparing three groups), N = 4–5 per group, ∧P<0.05 vs. control, 1 way ANOVA followed by Fisher’s Post Hoc Test.